Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
indoleamine 2,3-dioxygenase 1 small interfering RNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Systemic
01
Overview
Indoleamine 2,3-dioxygenase 1 (IDO1) small interfering RNA (siRNA) is a therapeutic modality designed to silence the expression of the IDO1 enzyme through RNA interference. IDO1 is a key enzyme in the kynurenine pathway that degrades tryptophan, leading to an immunosuppressive environment and contributing to chemoresistance in various malignancies, including ovarian cancer. By specifically targeting and degrading IDO1 mRNA, this siRNA approach reduces IDO1 protein levels, which has been shown to increase reactive oxygen species (ROS) accumulation and enhance p53-dependent apoptosis. This mechanism sensitizes cancer cells to platinum-based chemotherapy, such as cisplatin, and may help overcome resistance in type II ovarian cancer patients.
- Other names
- IDO1 small interfering RNAIDO-1 small interfering RNAIDO 1 small interfering RNAindoleamine 2,3-dioxygenase 1 siRNA
02
Targets
IDO1 (Indoleamine 2,3-dioxygenase 1)
Beyond the preview
Go deeper on indoleamine 2,3-dioxygenase 1 small interfering RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on indoleamine 2,3-dioxygenase 1 small interfering RNA.